FH and Uterine leiomyoma: Although not employed currently as a routine clinical screening method for HLRCC, we acquired an antibody directed against FH (J-13 fumarate hydratase, Santa Cruz Biotechnology, Santa Cruz, CA) and performed staining on the lesion using two benign uterine leiomyomas as positive controls.